Close Menu

lawsuit

The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.

The Delaware jury said Oxford Nanopore had infringed three patents, but also found that they were invalid, mostly because they were not enabled.

The US Court of Appeals for the Federal Circuit sent the case, which had been thrown out in December 2018, back to the trial court.

The company's original lawsuit, filed last March, accused Natera of infringing on two patents it holds in conjunction with Stanford University.

BioMérieux had alleged infringement of two of its patents associated with nucleotide sequences to detect HIV-1 subtypes. 

According to the complaint, the allegedly infringing products include all those that use nucleotides with a 3’-O-azidomethyl blocking group.

Add the Missing Data

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

BGI is planning to offer free trials of its MGI DNBSEQ-G400 sequencing system to key opinion leaders, a development Illumina is trying to stop.

CareDx first sued Natera in April 2019, accusing the company of trying to mislead patients and clinicians about the superiority of its Prospera transplant test.

The commission plans to bar Bio-Rad from importing certain single-cell products, potentially including the ddSeq Single-Cell Isolator and ddSeq cartridges.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.